Core Viewpoint - Enwei Pharmaceutical (301331.SZ) has signed a partnership agreement to invest in a venture capital fund focusing on early and growth-stage companies in the healthcare and technology sectors [1] Group 1: Investment Details - The company will act as a limited partner, contributing RMB 20 million to the investment fund, which represents a 9.9502% stake [1] - The partnership includes Shanghai Panlin Hongyu Enterprise Management Partnership (Limited Partnership), Tangshan Jinkun Chemical Co., Ltd., and Li Jiao Jiao [1] Group 2: Investment Focus - The venture capital fund will primarily invest in early and growth-stage enterprises [1] - Investment directions include healthcare (innovative drugs, innovative medical devices) and technology (enterprise-level services, hard technology) [1]
恩威医药(301331.SZ)：拟与专业投资机构共同投资设立基金